Drug repurposing for cancer therapy
Open accessThe DOI matches its Crossref record; 508 of the 513 references it cites were found in a registry or an index; 127 of the 249 sources its claims cite were checked for support.
Abstract
Comprehensive review of methods and candidate repurposed drugs for cancer therapy.
Overview
CoChat Summary
## TL;DR
This is a narrative review of drug repurposing for cancer therapy, summarizing experimental and computational strategies, hallmark-targeting examples, tumor microenvironment targets, and nanomaterial-based delivery. It argues that repurposed drugs may speed development and reduce cost, but clinical translation remains limited by bioavailability, dosing, toxicity, and regulatory barriers.
## Key findings
- The review organizes drug repurposing around the 14 hallmarks of cancer and the tumor microenvironment (TME), and notes that repurposed drugs may target multiple malignancy features and support combination therapy.
- It states that conventional drug development can take 10–15 years and cost $1–2 billion, whereas repurposing is faster and cheaper because existing drugs already have known safety, dosage, and toxicity profiles.
- The paper highlights several reported quantitative findings from prior studies, including a 45% risk reduction in thyroid cancer among metformin users in Eastern countries, and lower gynecological cancer occurrence with metformin: HR = 0.60 (95% CI: 0.49–0.74), endometrial cancer HR = 0.65 (95% CI: 0.50–0.85), and ovarian cancer HR = 0.47 (95% CI: 0.27–0.82).
- It also cites a phase I clinical trial of leflunomide in refractory multiple myeloma where disease stabilization occurred in 9 of 11 patients.
## Methods
- Design: Narrative review/systematic overview of published work on drug repurposing for cancer therapy, centered on hallmarks of cancer, TME-targeting therapy, and nanomaterial-based delivery.
- Data/sample: The text does not report a primary study sample; instead, it synthesizes examples from preclinical studies, epidemiological analyses, and clinical trials, and mentions use of databases and tables of repurposed-drug candidates.
- Main analysis: The paper categorizes repurposing strategies into experimental approaches (including phenotypic screening and organoid/tumoroid models) and computational approaches (including molecular docking, network analysis, data mining, similarity analysis, machine learning, and transcriptional signature methods).
## Limitations
- The paper explicitly states that many repurposed drugs have not yet translated into clinical application, and that clinical trial evidence is limited for several TME-targeting candidates.
- It notes several practical barriers: bioavailability limits, instability, poor solubility, toxicity, dosing uncertainty, patent/IP issues, regulatory barriers, and limited funding for trials.
- The text also makes evident, but does not present as a formal limitation, that much of the evidence discussed is preclinical and often based on small or ongoing clinical studies rather than large randomized trials.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
99 Valid · 15 Not valid · 82 Not checked · 27 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“Furthermore, TPL has been shown to induce autophagy-mediated caspase-independent cell death in tumor cells.”
§ Drug repurposing for cancer therapy > Drug repurposing: candidates for the therapeutic targeting of hallmarks of cancer > Inducing cell death
What the sources say
- Disputedcites [91] Zhao F Triptolide induces protective autophagy through activation of the CaMKKβ-AMPK signaling pathway in prostate cancer cells Oncotarget 2016 7 5366 5382 10.18632/oncotarget.6783 26734992 PMC4868692 sourceExperimental — accuracy not yet measured
The Results section (‘Triptolide induces cytoprotective autophagy in PCa cells’; page not supplied) concludes that autophagy protects prostate cancer cells from triptolide-induced death: inhibiting autophagy increased both cell death and caspase-3 cleavage. This is contrary to the attributed claim that triptolide-induced autophagy mediates caspase-independent cell death. (LLM, conf=0.90)
Checked by a reasoning model — may be wrong.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“Celecoxib has been shown to enhance the efficacy of BRAF/MEKi treatments in melanoma through suppression of the NF-κB pathway.”
§ Drug repurposing for cancer therapy > Drug repurposing: candidates for the therapeutic targeting of hallmarks of cancer > Targeting tumor-promoting inflammation
What the sources say
- Disputedcites [183] Vergani E miR-146a-5p impairs melanoma resistance to kinase inhibitors by targeting COX2 and regulating NFkB-mediated inflammatory mediators Cell Commun. Signal 2020 18 156 10.1186/s12964-020-00601-1 32967672 PMC7510138 sourceExperimental — accuracy not yet measured
The Results section (“Targeting COX2 restores melanoma sensitivity to BRAF/MEKi”; page unavailable) supports increased growth inhibition and cytotoxicity with celecoxib plus BRAF/MEKi in melanoma cells. But it reports noncanonical NF-κB activation, not suppression, and attributes the enhanced apoptotic effects to reduced PGE2 production. The Discussion likewise describes activation of NF-κB signaling cascades during celecoxib-induced cell death. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“Dong and colleagues reported the nuanced relationship between EGCG and the WNT/β-catenin signaling pathway by demonstrating that overexpression of β-catenin could either augment or reduce the anticancer effects of EGCG.147”
§ Drug repurposing for cancer therapy > Drug repurposing: candidates for the therapeutic targeting of hallmarks of cancer > Interfering with replication
What the sources say
- Disputedcites [147] Dong C Epigallocatechin-3-gallate suppresses the growth of human osteosarcoma by inhibiting the Wnt/β-catenin signalling pathway Bioengineered 2022 13 8490 8502 10.1080/21655979.2022.2051805 35348430 PMC9161922 sourceExperimental — accuracy not yet measured
In “EGCG inhibits OS growth by regulating the Wnt/β-catenin pathway” (Figure 4c–f; page not supplied), the paper reports that β-catenin overexpression inhibited EGCG’s antitumour and pro-apoptotic effects. It was β-catenin knockdown, not overexpression, that strengthened those effects. (LLM, conf=0.91)
Checked by a reasoning model — may be wrong.
hedgedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“Another extensive meta-analysis ascertained a notably lower gynecological cancer occurrence in those undergoing metformin treatment compared to alternative therapies (gynecological cancer: HR = 0.60, 95% CI: 0.49–0.74; endometrial cancer: HR = 0.65, 95% CI: 0.50–0.85; ovarian cancer: HR = 0.47, 95% CI: 0.27–0.82).203”
§ Drug repurposing for cancer therapy > Drug repurposing: candidates for the therapeutic targeting of hallmarks of cancer > Locking phenotypic plasticity
What the sources say
- Disputedcites [203] Yao K Zheng H Li T Association between metformin use and the risk, prognosis of gynecologic cancer Front. Oncol. 2022 12 942380 10.3389/fonc.2022.942380 35898873 PMC9309370 sourceExperimental — accuracy not yet measured
The Discussion section on cancer risk (page not provided) reports no significant association between metformin use and the occurrence of gynecological, endometrial, or ovarian cancer in women with diabetes. The cited hazard ratios appear instead in the Discussion section on prognosis, where they describe overall survival among patients with cancer, not cancer occurrence. (LLM, conf=0.90)
Checked by a reasoning model — may be wrong.
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Notably, high-throughput screening using sophisticated models can identify compounds that mitigate disease symptoms without necessitating pre-existing knowledge about the drug-target interactions.29,30”
§ Drug repurposing for cancer therapy > Drug repurposing strategies
What the sources say
- Partly supportedcites [29] Huang H Zhang P Qu XA Sanseau P Yang L Systematic prediction of drug combinations based on clinical side-effects Sci. Rep. 2014 4 7160 10.1038/srep07160 25418113 PMC4241517 sourceExperimental — accuracy not yet measured
The Abstract (page unavailable) describes a computational model that uses clinical side effects to predict drug combinations, rather than requiring drug-target interaction data. But it does not show that the predicted compounds mitigate disease symptoms; the Discussion (page unavailable) says the predictions need experimental testing. The Abstract also distinguishes this approach from high-throughput screening, which it says is impractical for all possible combinations. (LLM, conf=0.86)
- Could not verifycites [30] Kuhn M Campillos M Letunic I Jensen LJ Bork P A side effect resource to capture phenotypic effects of drugs Mol. Syst. Biol. 2010 6 343 10.1038/msb.2009.98 20087340 PMC2824526 sourceExperimental — accuracy not yet measured
The Introduction (page unavailable) discusses databases of cellular phenotypes and the potential of large-scale computational methods; it does not describe screening sophisticated models to find compounds that relieve disease symptoms. Searches for high-throughput screening, symptom mitigation, and drug-target-independent screening found no passage addressing that claim. (LLM, conf=0.73)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
113 more claims · 51 with their cited sources checked
Create a free account to see all 223 claims and to verify the 21 references still open.
- It may state two separate claims as one. 87
- Probably not a substantial claim. 25
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Self-check results appear here once an independent check has confirmed them.
Cited works that were retracted
Works this paper cites that were later retracted, from the retraction notices publishers deposit. Major when the notice came out before this paper was published.
A note, not an issue: for example, a cited work that was retracted only after this paper was published, which its authors could not have known.
In the paper
“134 Ongoing clinical trials are currently examining the ef fi cacy of simvastatin against various cancers, including breast (NCT00807950, NCT05550415), gastric (NCT01099085, NCT03086291), colorectal (NCT01238094), and bladder (NCT02360618) cancer.”
Cited work 10.1038/cddis.2017.46 · retracted 2025-11-27 · notice 10.1038/s41419-025-08275-8 · this paper published 2024-04-19
Citations
Cites
1 retracted
Items 401–508 of 508
De Lellis, L., Veschi, S., Tinari, N., Mokini, Z., Carradori, S., Brocco, D., Florio, R., Grassadonia, A., & Cama, A. (2021) · Cancers · doi:10.3390/cancers13163946 · Cited by 40 · cited 1×
“387 Clinical trials are essential for addressing questions about whether different pharmacodynamic and pharmacokinetic properties are required for their activity in speci fi c settings also remain.”
BackgroundVergani, E., Dugo, M., Cossa, M., Frigerio, S., Di Guardo, L., Gallino, G., Mattavelli, I., Vergani, B., Lalli, L., Tamborini, E., et al. (2020) · Cell Communication and Signaling · doi:10.1186/s12964-020-00601-1 · Cited by 39 · cited 1×
“183 Interestingly, Zhang et al. reported that celecoxib increased PTEN protein expression while inhibiting NF-κ B and phosphatase of regenerating liver-3 expression levels in HCC-af fl icted mouse livers.”
BackgroundEpidemiological Evidences on Dietary Flavonoids and Breast Cancer Risk: A Narrative Review
Sak, K. (2017) · PubMed Central · doi:10.22034/apjcp.2017.18.9.2309 · Cited by 39 · cited 1×
“171,172 These discrepancies have fueled a surge of interest within the scienti fi c community, which has prompted rigorous studies into the potential role of genistein in cancer prevention and suppression of tumor growth.”
BackgroundDrug repurposing: Iron in the fire for older drugs
Sonaye, H. V., Sheikh, R. Y., & Doifode, C. A. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111638 · Cited by 39
Overcoming Therapy Resistance in Colon Cancer by Drug Repurposing
Zarif, T. E., Yibirin, M., Oliveira-Gomes, D. D., Machaalani, M., Nawfal, R., Carlini, G. B., Bahmad, H. F., & Bitar, N. (2022) · Cancers · doi:10.3390/cancers14092105 · Cited by 39 · cited 1×
“388 In addition, several key points warrant particular attention.”
BackgroundCelastrol functions as an emerging manager of lipid metabolism: Mechanism and therapeutic potential
Gu, J., Shi, Y., Zhu, N., Li, H., Zhang, C., & Li, Q. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114981 · Cited by 39 · cited 1×
“355,356 To circumvent these challenges, Ding et al. innovatively encapsulated celastrol into SF nanoparticles (CL-SFNPs) using a modi fi ed desolvation method and found that CL-SFNPs outperformed free-form celastrol in terms of antitumor ef fi cacy, inhibition of colony formation, and induction of…”
MethodLo, Y., Senese, S., France, B., Gholkar, A. A., Damoiseaux, R. D., & Torres, J. Z. (2017) · Scientific Reports · doi:10.1038/s41598-017-11508-2 · Cited by 38
Lalla, R. V., Choquette, L. E., Curley, K. F., Dowsett, R. J., Feinn, R., Hegde, U. P., Pilbeam, C. C., Salner, A., Sonis, S. T., & Peterson, D. E. (2014) · Oral Oncology · doi:10.1016/j.oraloncology.2014.08.001 · Cited by 37
Khutornenko, A. A., Dalina, A. A., Chernyak, B. V., Chumakov, P. M., & Evstafieva, A. G. (2014) · Acta Naturae · doi:10.32607/20758251-2014-6-1-69-75 · Cited by 37 · cited 1×
“107 Le fl unomide has also been shown to suppress melanoma growth by impeding the effective transcription elongation of requisite genes.”
BackgroundLu, X., Li, Y., Yang, W., Tao, M., Dai, Y., Xu, J., & Xu, Q. (2021) · Journal of Biochemical and Molecular Toxicology · doi:10.1002/jbt.22621 · Cited by 37 · cited 1×
“123 In addition, synthetic derivatives of OA, such as CDDO-Im, have been shown to block the EGFR/signal transducer and activator of transcription 3 (STAT3)/Sox-2 signaling pathway in tumor-associated macrophages (TAMs), which have been implicated in promoting breast cancer proliferation and…”
BackgroundLiu, X., Li, P., Hirayama, R., Niu, Y., Liu, X., Chen, W., Jin, X., Zhang, P., Ye, F., Zhao, T., et al. (2018) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2018.04.005 · Cited by 36 · cited 1×
“174 Finally, genistein has also been shown to reduce NNKAc-induced ROS and DNA damage through the activation of Nrf2, demonstrating its protective role against oxidative stress and DNA damage.”
BackgroundDrug Repositioning in Oncology
Serafin, M. B., Bottega, A., da Rosa, T. F., Machado, C. D. S., Foletto, V. S., Coelho, S. S., da Mota, A. D., & Hörner, R. (2019) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000000906 · Cited by 36
Du, C., Guan, X., Liu, Y., Xu, Z., Du, X., Li, B., Wang, M., & Zheng, Z. (2022) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-022-04398-3 · Cited by 36
Oleanolic acid regulates the Treg/Th17 imbalance in gastric cancer by targeting IL-6 with miR-98-5p
Xu, Q.-F., Peng, H.-P., Lu, X.-R., Hu, Y., Xu, Z.-H., & Xu, J.-K. (2021) · Cytokine · doi:10.1016/j.cyto.2021.155656 · Cited by 36
Gao, R., Wu, X., Huang, Z., Wang, B., Li, F., Xu, H., & Ran, L. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s182405 · Cited by 35 · cited 1×
“277 Despite these encouraging results, few clinical trials have focused on emodin due to its limited bioavailability.”
BackgroundSuraweera, T. L., Merlin, J. P. J., Dellaire, G., Xu, Z., & Rupasinghe, H. P. V. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24043676 · Cited by 35 · cited 1×
“175 To date, numerous clinical trials have been initiated to determine the therapeutic potential of genistein against various types of cancer, including NSCLC (NCT01628471), pancreatic cancer (NCT00376948), and breast cancer (NCT00769990).”
BackgroundElkind-Hirsch, K. E., Paterson, M. S., Seidemann, E. L., & Gutowski, H. C. (2016) · Fertility and Sterility · doi:10.1016/j.fertnstert.2016.09.023 · Cited by 35
Katara, G. K., Kulshrestha, A., Jaiswal, M. K., Pamarthy, S., Gilman-Sachs, A., & Beaman, K. D. (2016) · Oncogene · doi:10.1038/onc.2015.159 · Cited by 34
Angiogenesis inhibitors for the treatment of epithelial ovarian cancer
Gaitskell, K. L., Rogozińska, E., Platt, S., Chen, Y., Aziz, M. A. A. E., Tattersall, A., & Morrison, J. (2023) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007930.pub3 · Cited by 34
Redrawing therapeutic boundaries: microbiota and cancer
Sholl, J., Sepich‐Poore, G. D., Knight, R. D., & Pradeu, T. (2021) · Trends in cancer · doi:10.1016/j.trecan.2021.10.008 · Cited by 33 · cited 1×
“220 Inulin .”
Zhang, Z., Garzotto, M. G., Beer, T. M., Thuillier, P., Lieberman, S. F., Mori, M., Stoller, W. A., Farris, P. E., & Shannon, J. (2016) · Nutrition and Cancer · doi:10.1080/01635581.2016.1224365 · Cited by 33
Zeng, Q., Nie, X., Li, L., Liu, H.-F., Peng, Y.-Y., Zhou, W.-T., Hu, X.-J., Xu, X.-Y., & Chen, X.-L. (2022) · Journal of Natural Products · doi:10.1021/acs.jnatprod.1c00950 · Cited by 33 · cited 1×
“81 These preclinical fi ndings suggest that repurposing salidroside as a potential anticancer agent is worthwhile.”
BackgroundGuo, D., Jin, J., Liu, J., Wang, Y., Li, D., & He, Y. (2022) · Drug Design, Development and Therapy · doi:10.2147/dddt.s370114 · Cited by 33 · cited 1×
“211 BE is a major component of PC-SPES, a herbal concoction enriched with Scutellaria baicalensis , which was meticulously formulated under strict quality controls, and investigated in a phase 1 clinical trial in 2008.”
BackgroundThe emerging regulatory roles of non-coding RNAs associated with glucose metabolism in breast cancer
Kansara, S., Singh, A., Badal, A. K., Rani, R., Baligar, P., Garg, M., & Pandey, A. K. (2023) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2023.06.007 · Cited by 32 · cited 1×
“98 Current research on metabolic reprogramming has primarily focused on the aberrant activation of the PI3K/AKT/mTOR pathway, as well as activation of oncoproteins such as MYC, RAS, pyruvate kinase M2 (PKM2), and hypoxia-inducible factor 1 (HIF-1).”
BackgroundEffect of multiple‐dose osimertinib on the pharmacokinetics of simvastatin and rosuvastatin
Harvey, R. D., Aransay, N. R., Isambert, N., Lee, J., Arkenau, H., Vansteenkiste, J., Dickinson, P. A., Bui, K., Weilert, D. K., So, K., et al. (2018) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13753 · Cited by 32
Onco-cardiology: Drug-drug interactions of antineoplastic and cardiovascular drugs
Akbulut, İ. M., & Ürün, Y. (2019) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2019.102822 · Cited by 32 · cited 1×
“13,397 In addition, the design and execution of clinical trials are crucial for drug repurposing strategies.”
BackgroundRepurposing drugs targeting metabolic diseases for cancer therapeutics
Pillai U, J., Ray, A., Maan, M., & Dutta, M. (2023) · Drug Discovery Today · doi:10.1016/j.drudis.2023.103684 · Cited by 31
Self-Assembling Colloidal System for the Ocular Administration of Cyclosporine A
Luschmann, C., Tessmar, J., Schoeberl, S., Strau, O., Luschmann, K., & Goepferich, A. (2014) · Cornea · doi:10.1097/ico.0b013e3182a7f3bf · Cited by 31
Jóźwiak, P., Ciesielski, P., Zaczek, A., Lipińska, A., Pomorski, L., Wieczorek, M., Bryś, M., Forma, E., & Krześlak, A. (2017) · Journal of Biomedical Science · doi:10.1186/s12929-017-0388-y · Cited by 31 · cited 1×
“301 Moreover, in an in vivo subcutaneous lung tumor transplantation model in rats, intraperitoneal injections of ascorbic acid (1 g/kg) were found to reduce HIF-1 α expression within the tumor, while simultaneously suppressing tumor growth and reducing vascular density.”
BackgroundKralova, V., Hanušová, V., Caltová, K., Špaček, P., Hochmalová, M., Skálová, L., & Rudolf, E. (2018) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2018.07.026 · Cited by 30 · cited 1×
“162,163 Recent anecdotal evidence from two case reports has further supported the possibility of MBZ being repurposed as an anticancer drug by documenting its success in managing metastatic patients.”
BackgroundDrug delivery for metabolism targeted cancer immunotherapy
Khodaei, T., Inamdar, S., Suresh, A. P., & Acharya, A. P. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114242 · Cited by 30 · cited 1×
“346 Thus, it is crucial to devise the right therapeutic strategies to enhance their impact on tumor growth, while minimizing side effects and drug resistance.”
BackgroundLiu, Y., Hu, Z., Xing, H., Kang, L., Chen, X., Liu, B., & Niu, K. (2022) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2022.10.074 · Cited by 30
Advances in mitophagy and mitochondrial apoptosis pathway-related drugs in glioblastoma treatment
Li, W., & Xu, X. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1211719 · Cited by 30 · cited 1×
“391 In terms of drug repurposing, this implies that certain drugs might show ef fi cacy across multiple cancer types, especially those targeting these common mechanisms.”
BackgroundManni, A., Richie, J. P., Schetter, S. E., et al. (2017) · European Journal of Clinical Nutrition · doi:10.1038/ejcn.2016.273 · Cited by 29
Xie, J., Liu, J., Zhao, M., Li, X., Wang, Y., Zhao, Y., Cao, H., Ji, M., Chen, M., & Hou, P. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24043418 · Cited by 29
Stemming Colorectal Cancer Growth and Metastasis: HOXA5 Forces Cancer Stem Cells to Differentiate
Tan, S. H., & Barker, N. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.11.004 · Cited by 29 · cited 1×
“187,188 Speci fi cally, SMAD4 can promote differentiation, thereby suppressing WNT-induced proliferation.”
BackgroundDeciphering Signaling Pathway Networks to Understand the Molecular Mechanisms of Metformin Action
Sun, J., Zhao, M., Jia, P., Lily, W., Wu, Y., Carissa, I., Zhou, Y., Bowton, E., Roden, D. M., Denny, J. C., et al. (2015) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1004202 · Cited by 28
Drug repurposing: An emerging strategy in alleviating skin cancer
Kumbhar, P., Kole, K., Yadav, T., Bhavar, A., Waghmare, P., Bhokare, R., Manjappa, A., Jha, N. K., Chellappan, D. K., Shinde, S., et al. (2022) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2022.175031 · Cited by 28 · cited 1×
“348 In this section, we catalog the various nano-carriers tailored for the targeted delivery of repurposed drugs against tumors, alongside ongoing clinical trials that are using nanomaterials to treat cancer.”
BackgroundTumors smother their epigenome
Thienpont, B., Dyck, L. V., & Lambrechts, D. (2016) · Molecular & Cellular Oncology · doi:10.1080/23723556.2016.1240549 · Cited by 28
Wu, H., Van Der Pol, W. J., Dubois, L. G., Morrow, C. D., & Tollefsbol, T. O. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24109015 · Cited by 27 · cited 1×
“225 Furthermore, inulin has been credited with fostering the proliferation of bene fi cial gut fl ora while impeding the growth of deleterious bacteria in an animal model harboring the murine pks + E. coli strain NC101.”
BackgroundOverview of Medicinally Important Diterpenoids Derived from Plastids
Zhang, L., & Lu, S. (2017) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/1389557516666160614005244 · Cited by 26 · cited 1×
“88 Speci fi cally, cells exposed to TPL were found to undergo non-apoptotic cell death.”
BackgroundBaxevanis, A. D. (2012) · Current Protocols in Human Genetics · doi:10.1002/0471142905.hg0913s73 · Cited by 26
Husain, K., Villalobos-Ayala, K., Laverde, V., Vazquez, O. A., Miller, B., Kazim, S., Blanck, G., Hibbs, M. L., Krystal, G., Elhussin, I., et al. (2022) · Cancers · doi:10.3390/cancers14153613 · Cited by 26
SHEN, W., ZOU, X., CHEN, M., SHEN, Y., HUANG, S., GUO, H., ZHANG, L., & LIU, P. (2013) · Oncology Reports · doi:10.3892/or.2013.2524 · Cited by 26 · cited 1×
“…studies, indicating that potential downstream effectors, such as the dephosphorylation of low-density lipoprotein receptor-related protein 6 and the inhibition of WNT/ β -catenin 312 or PI3K/AKT/mTOR/HIF-1 α signaling pathways, 313 follow the inhibition of V-type H + ATPase by PPIs in GC cells.”
BackgroundComparable outcomes of patients eligible vs ineligible for SWOG leukemia studies
Statler, A. B., Othus, M. K. D., Erba, H. P., Chauncey, T. R., Radich, J. P., Coutre, S. E., Advani, A. S., Nand, S., Ravandi, F., Mukherjee, S., et al. (2018) · Blood · doi:10.1182/blood-2018-01-826693 · Cited by 25
Senescence: A program in the road to cell elimination and cancer
Moiseeva, O., Guillon, J., & Ferbeyre, G. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.12.017 · Cited by 25 · cited 1×
“229 – 231 For example, DOX-induced systemic senescence was found to promote metastasis in an orthotopic mouse model of breast cancer.”
BackgroundBlumenstein, B. A., Fred Saad, C., Hotte, S. J., Chi, K. N., Eigl, B. J., Gleave, M. E., & Jacobs, C. A. (2013) · Cancer Medicine · doi:10.1002/cam4.93 · Cited by 25
Dong, C., Wang, Z., Shen, P., Chen, Y., Wang, J., & Wang, H. (2022) · Bioengineered · doi:10.1080/21655979.2022.2051805 · Cited by 25 · cited 1×
“147 In addition, another study found that EGCG was involved in reducing the mRNA expression and transcriptional activity of β -catenin in wild-type P53-expressing KB cells.”
BackgroundEvaluation of usage patterns and user perception of the drug–drug interaction database SFINX
Andersson, M. L., Böttiger, Y., Bastholm‐Rahmner, P., Ovesjö, M., Vég, A., & Eiermann, B. (2015) · International Journal of Medical Informatics · doi:10.1016/j.ijmedinf.2015.01.013 · Cited by 24
Rabben, H.-L., Andersen, G. T., Ianevski, A., Olsen, M. K., Kainov, D., Grønbech, J. E., Wang, T. C., Chen, D., & Zhao, C.-M. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.625991 · Cited by 24 · cited 1×
“…experimental approach considers tools such as induced pluripotent stem cell models and function-fi rst phenotypic screenings (or reverse chemical biology), 25,26 while computational methods use target-centric, knowledge-driven, signature-aligned, pathway-focused, and mechanism-speci fi c strategies.”
MethodKim, N. Y., Jung, Y. Y., Yang, M. H., Chinnathambi, A., Govindasamy, C., Narula, A. S., Namjoshi, O. A., Blough, B. E., & Ahn, K. S. (2022) · Biochimie · doi:10.1016/j.biochi.2022.05.018 · Cited by 24 · cited 1×
“94 In addition, Tanshinone IIA has been shown to induce ferroptosis in gastric cancer (GC) cells through p53-mediated down-regulation of solute carrier family 7 member 11 (SLC7A11), leading to elevated levels of reactive oxygen species (ROS), lipid peroxidation, and iron accumulation, and…”
BackgroundJoe, N. S., Godet, I., Milki, N., Ain, N. U. I., Oza, H. H., Riggins, G. J., & Gilkes, D. M. (2022) · Breast Cancer Research · doi:10.1186/s13058-022-01591-3 · Cited by 24
D'Amico, A. V., Xie, W., McMahon, E., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.00596 · Cited by 24
A BASIS FOR SYMPATHECTOMY FOR CANCER OF THE CERVIX UTERI
Pereira, A. S. (1946) · Archives of Surgery · doi:10.1001/archsurg.1946.01230050265003 · Cited by 23 · cited 1×
“318 More recently, groundbreaking research has revealed that tumors can actively recruit nerves into the TME, which can then directly promote tumor growth — a phenomenon known as “ tumor innervation ” .”
BackgroundDiscovery of a novel CDK7 inhibitor YPN-005 in small cell lung cancer
Choi, Y. J., Lee, H., Kim, D., et al. (2021) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2021.174298 · Cited by 23 · cited 1×
“43 A high-throughput screening, based on the interaction between patient-derived breast cancer organoids and tumor-speci fi c cytotoxic T cells, identi fi ed three epigenetic inhibitors - BML-210, GSK-LSD1, and CUDC-101 — that displayed signi fi cant antitumor effects.”
BackgroundDrug Repurposing in Oncology: Current Evidence and Future Direction
Zhang, Z., Ji, J., & Liu, H. (2020) · Current Medicinal Chemistry · doi:10.2174/0929867327999200820124111 · Cited by 22 · cited 1×
“377 In this review, we have drawn on an expansive exploration of drug repurposing research over the years to collate and appraise potential drug candidates for cancer therapy, the relevant clinical studies of which are presented in Table 3.”
BackgroundLiu, S., Li, Y., & Li, Z. (2022) · Cell Cycle · doi:10.1080/15384101.2021.2019976 · Cited by 21 · cited 1×
“79 Similarly, Liu et al. showed that salidroside suppressed proliferation, colony formation, and migration of the PC3 and DU145 prostate cancer cell lines in a dose-dependent manner by inhibiting the PI3K/AKT pathway.”
BackgroundQin, X., Li, T., Li, S., Yang, H., Wu, C., Zheng, C., You, F., & Liu, Y. (2019) · Cellular and Molecular Immunology · doi:10.1038/s41423-019-0282-5 · Cited by 21 · cited 1×
“282 287 Many studies have focused on the cellular proteins involved in mechanosensing, such as integrins and focal adhesion proteins, and their associated molecular mechanisms including cytoskeleton remodeling, integrin signaling, Rho signaling, and Hippo signaling.”
BackgroundPoonpanichakul, T., Shiao, M., Jiravejchakul, N., Matangkasombut, P., Sirachainan, E., Charoensawan, V., & Jinawath, N. (2021) · Bioscience Reports · doi:10.1042/bsr20212093 · Cited by 20 · cited 1×
“11,12 Therefore, there remains an urgent need to develop novel treatment strategies with high anti-tumor ef fi cacy and minimal side effects.”
BackgroundYu, A. F., Moore, Z., Moskowitz, C. S., et al. (2023) · JAMA Cardiology · doi:10.1001/jamacardio.2023.1229 · Cited by 20
Wang, C., Lan, T., Chen, Z., Wang, X., Han, Y., Yang, N., Xu, Z., Li, H., Tao, M., & Song, Y. (2023) · Journal of Food Science · doi:10.1111/1750-3841.16772 · Cited by 20 · cited 1×
“223 Intriguingly, experimental studies on animal models have revealed that oral administration of inulin gel signi fi cantly ampli fi es the ef fi cacy of immune checkpoint therapy while maintaining an admirable safety pro fi le.”
BackgroundRepurposing Drugs for Acute Myeloid Leukemia: A Worthy Cause or a Futile Pursuit?
Wojcicki, A. V., Kadapakkam, M., Frymoyer, A. R., Lacayo, N. J., Chae, H.-D., & Sakamoto, K. M. (2020) · Cancers · doi:10.3390/cancers12020441 · Cited by 20 · cited 1×
“386 This article provides a summary of the most frequently employed approaches to drug repurposing, including both experimental and computational methodologies.”
MethodRader, J. S., Sill, M. W., Beumer, J. H., et al. (2017) · Gynecologic Oncology · doi:10.1016/j.ygyno.2017.02.040 · Cited by 20
A narrative review of antibody–drug conjugates in EGFR-mutated non-small cell lung cancer
Hsu, R. C., & Benjamin, D. J. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1252652 · Cited by 20 · cited 1×
“396 Therefore, when considering drug repurposing, the speci fi c characteristics and needs of each cancer type must be taken into account.”
BackgroundInulin impacts tumorigenesis promotion by colibactin-producing Escherichia coli in ApcMin/+ mice
Oliero, M., Hajjar, R., Cuisiniere, T., Fragoso, G., Calvé, A., & Santos, M. M. (2023) · Frontiers in Microbiology · doi:10.3389/fmicb.2023.1067505 · Cited by 19 · cited 1×
“226 In summary, inulin possesses a range of physiological bene fi ts, with a particularly pronounced impact on cancer therapeutics.”
BackgroundJang, B.-Y., Shin, M., Han, D.-H., & Sung, J.-S. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15112627 · Cited by 19 · cited 1×
“292 In addition, Mao et al. demonstrated that curcumin suppressed proliferation of LGR5( + ) colorectal CSCs by not only promoting autophagy but also through transcriptional repression of the oncogenic transcription factor activating enhancer-binding protein 2A (TFAP2A)-regulated ECM pathway.”
BackgroundNwanaji-Enwerem, J. C., Chung, F. F.-L., Van der Laan, L., Novoloaca, A., Cuenin, C., Johansson, H., Bonanni, B., Hubbard, A. E., Smith, M. T., Hartman, S. J., et al. (2021) · Clinical Epigenetics · doi:10.1186/s13148-021-01218-y · Cited by 19
Celecoxib could reverse the hypoxia-induced Angiopoietin-2 upregulation in gastric cancer
Wang, J., Wu, K., Bai, F., Zhai, H., Xie, H., Du, Y., Liang, J., Han, S., Chen, Y., Lin, T., et al. (2005) · Cancer Letters · doi:10.1016/j.canlet.2005.10.030 · Cited by 19 · cited 1×
“178 However, recent studies have described the anticancer properties of celecoxib, which are mediated through the suppression of COX-2, a factor that is closely associated with cancer-related in fl ammation by promoting the synthesis of various prostaglandins, such as prostaglandin E2 (PGE2).”
BackgroundKemnade, J. O., Florez, M. A., Sabichi, A. L., Zhang, J., Jhaveri, P. M., Chen, G., Chen, A. C., Miller-Chism, C. N., Bulsara, S., Hilsenbeck, S. G., et al. (2023) · Oral Oncology · doi:10.1016/j.oraloncology.2023.106536 · Cited by 19
Nakanishi, K., Hiramoto, K., & Ooi, K. (2021) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b21-00089 · Cited by 18 · cited 1×
“302 Furthermore, a retrospective analysis involving human patient tumor samples paired with controls for endometrial cancer, RCC, and CRC revealed that tumors exhibiting the highest HIF-1 activity were generally associated with patients who had a notable de fi ciency in ascorbic acid.”
BackgroundJalilian, E., Abolhasani-Zadeh, F., Afgar, A., Samoudi, A., Zeinalynezhad, H., & Langroudi, L. (2023) · Scientific Reports · doi:10.1038/s41598-023-48073-w · Cited by 18 · cited 1×
“291 The potential of curcumin to reduce metastasis of breast cancer is also evident in its inhibition of CXCL12/CXCR4 axis-mediated activation of the differentiation of adipose-derived MSCs (ADMSCs) into CAFs.”
BackgroundAssociation Between Metformin Use and the Risk, Prognosis of Gynecologic Cancer
Yao, K., Zheng, H., & Li, T. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.942380 · Cited by 18
Uncovering novel repositioning opportunities using the Open Targets platform
Khaladkar, M., Koscielny, G., Hasan, S., Agarwal, P., Dunham, I., Rajpal, D. K., & Sanséau, P. (2017) · Drug Discovery Today · doi:10.1016/j.drudis.2017.09.007 · Cited by 18
Kryeziu, K., Moosavi, S. H., Bergsland, C. H., Guren, M. G., Eide, P. W., Totland, M. Z., Lassen, K., Abildgaard, A., Nesbakken, A., Sveen, A., et al. (2021) · Journal of Translational Medicine · doi:10.1186/s12967-021-03062-3 · Cited by 17
CURRENT EPIDEMIOLOGICAL KNOWLEDGE ABOUT THE ROLE OF FLAVONOIDS IN PROSTATE CARCINOGENESIS
Sak, K. (2017) · Experimental Oncology · doi:10.31768/2312-8852.2017.39(2):98-105 · Cited by 17 · cited 1×
“171,172 These discrepancies have fueled a surge of interest within the scienti fi c community, which has prompted rigorous studies into the potential role of genistein in cancer prevention and suppression of tumor growth.”
BackgroundMiyajima, C., Hayakawa, Y., Inoue, Y., Nagasaka, M., & Hayashi, H. (2022) · Pharmaceuticals · doi:10.3390/ph15081015 · Cited by 17 · cited 1×
“133 Moreover, certain statins, notably simvastatin and atorvastatin, have been shown to downregulate MCM7 and RB expression.”
BackgroundJoshi, S. S., Catenacci, D. V. T., Karrison, T. G., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1483 · Cited by 16 · cited 1×
“384 However, many components (materials) of the nanocarriers that have exhibited excellent tumor targeting and therapeutic properties in a xenograft tumor model have not been tested for safety and their long-term toxicity is not known.”
BackgroundNanoliposomal Encapsulation Enhances In Vivo Anti-Tumor Activity of Niclosamide against Melanoma
Hatamipour, M., Jaafari, M. R., Momtazi‐Borojeni, A. A., Ramezani, M., & Sahebkar, A. (2019) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520619666190705120011 · Cited by 16 · cited 1×
“369 These promising outcomes highlight the potential of using a reinvigorated strategy such as NIC-loaded liposomes in cancer therapeutics.”
BackgroundPapaioannou, L., & Avgoustakis, K. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.114075 · Cited by 16 · cited 1×
“…safety nanomedicines such as nab-paclitaxel (Abrax-ane), liposomal DOX, liposomal vertepor fi n (Visudine), and gadolinium nanoparticles (AGuIX) 379 in cancers such as pancreatic cancer, 380 advanced squamous NSCLC, 381 breast cancer, 382 platinum-refractory metastatic urothelial cancer, 383…”
BackgroundMarlatt, K. L., Steinberger, J., Rudser, K. D., Dengel, D. R., Sadak, K. T., Lee, J. L., Blaes, A. H., Duprez, D. A., Perkins, J. L., Ross, J. A., et al. (2017) · Journal of Adolescent and Young Adult Oncology · doi:10.1089/jayao.2017.0075 · Cited by 16
Phase I trial of PC-Spes2 in advanced hormone refractory prostate cancer
Shabbir, M., Love, J., & Montgomery, B. (2008) · Oncology Reports · doi:10.3892/or.19.3.831 · Cited by 16 · cited 1×
“212 Despite these promising results, further studies are required to elucidate the intricate mechanisms and better understand the broader implications of using BE as a potential therapeutic agent for the treatment of cancer.”
BackgroundLipid-lowering drugs and cancer: an updated perspective
Alizadehasl, A., Alavi, M. S., Boudagh, S., Alavi, M. S., Mohebi, S., Aliabadi, L., Akbarian, M., Ahmadi, P., Mannarino, M. R., & Sahebkar, A. (2023) · Pharmacological Reports · doi:10.1007/s43440-023-00553-6 · Cited by 15 · cited 1×
“392 – 395 However, the diversity of cancers is equally important.”
BackgroundCelecoxib in lymphangioleiomyomatosis: results of a phase I clinical trial
El‐Chemaly, S., Taveira‐DaSilva, A. M., Bagwe, S., Klonowska, K., Machado, T. R., Lamattina, A. M., Goldberg, H. J., Jones, A. M., Julien-Williams, P. A., Maurer, R., et al. (2020) · European Respiratory Journal · doi:10.1183/13993003.02370-2019 · Cited by 15
Salidroside suppresses proliferation and migration in prostate cancer via the PI3K/AKT pathway
Liu, R.-H., Ma, T.-F., Yang, Q., Xiao, W.-C., Yin, L., Yin, M., Zhang, J.-S., & Wang, C.-H. (2023) · Cancer Biomarkers · doi:10.3233/cbm-220454 · Cited by 14 · cited 1×
“80 In addition, salidroside was found to impede cancer cell proliferation in HeLa cells and a subcutaneous HeLa-ADR-luc (doxorubicin-resistant derived HeLa-cell lines) cell xenograft mouse model through the activation of apoptosis and inhibition of the PI3K/ Akt/HIF-1 α signaling pathway.”
BackgroundStructure-based design of potent inhibitors of EGF-receptor tyrosine kinase as anti-cancer agents.
Ghosh, S., Narla, R. K., Zheng, Y., et al. (1999) · PubMed · Cited by 14
Del Pinto, R., Ferri, C., & Parati, G. (2020) · Journal of Hypertension · doi:10.1097/hjh.0000000000002334 · Cited by 13
Shin, Y. B., Choi, J., Shin, D. H., & Lee, J. (2023) · International Journal of Nanomedicine · doi:10.2147/ijn.s394712 · Cited by 13 · cited 2×
“352 This collaborative application of a nanocarrier system, therefore, has the potential to re-engineer RAPA, initially developed as a non-tumoricidal drug, into a formidable tumoricidal agent, thus making it a potent strategy in the chemoprevention of cancer.”
BackgroundDavies, O. M. T., Garzón, M. C., Frieden, I. J., Cottrell, C. E., Gripp, K. W., Saneto, R. P., Shwayder, T., Mirzaa, G., & Drolet, B. A. (2021) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2021.06.877 · Cited by 13
Roy, S., Malone, S. C., Grimes, S., & Morgan, S. C. (2020) · Clinical Oncology · doi:10.1016/j.clon.2020.09.005 · Cited by 13
Zhang, J., Wei, W., Zhong, Q., Feng, K., Yang, R., & Jiang, Q. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e16996 · Cited by 12 · cited 1×
“162,163 Recent anecdotal evidence from two case reports has further supported the possibility of MBZ being repurposed as an anticancer drug by documenting its success in managing metastatic patients.”
BackgroundFox, E., Busch, C. M., DeBernardo, A., Segers, B., Gottschalk, J., Womer, R. B., Balamuth, N., Bagatell, R., & Balis, F. M. (2021) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-021-04248-8 · Cited by 12
Limbu, K. R., Chhetri, R. B., Oh, Y. S., Baek, D. J., & Park, E.-Y. (2022) · Molecules · doi:10.3390/molecules27238127 · Cited by 12 · cited 1×
“161 MBZ has also been found to restrict the migratory and invasive tendencies of glioblastoma cells, and concurrently modulate pivotal markers in the EMT, suggesting a potential role for MBZ in mitigating glioblastoma metastasis.”
BackgroundLundgren, J. A., Kim, S. H., Solorzano, C. M. B., McCartney, C. R., & Marshall, J. C. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-02068 · Cited by 12
Gatti-Mays, M. E., Venzon, D. J., Galbo, C. E., Singer, A. J., Reynolds, J. C., Makariou, E. V., Kallakury, B., Heckman‐Stoddard, B. M., Korde, L. A., Isaacs, C. J., et al. (2016) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-15-0269 · Cited by 12
Will metformin use lead to a decreased risk of thyroid cancer? A systematic review and meta-analyses
Li, H., Chen, Y., Hu, L., Yang, W., Gao, Z., Liu, M., Tao, H., & Li, J. (2023) · European Journal of Medical Research · doi:10.1186/s40001-023-01287-0 · Cited by 10
Garmhausen, M. R., Hofmann, F., Senderov, V., Thomas, M., Kandel, B. A., & Habermann, B. H. (2015) · BMC Genomics · doi:10.1186/s12864-015-2017-z · Cited by 9
Hu, X., Wu, X., Liu, H., Cheng, Z., Zhao, Z., Xiang, C., Feng, X., Takeda, S., & Qing, Y. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.27082 · Cited by 9
A multi-layer omics approach to cancer
Waldron, D. (2016) · Nature Reviews Genetics · doi:10.1038/nrg.2016.95 · Cited by 8 · cited 1×
“27,31,32 In summary, although the idea of drug repurposing is long-established, it is only recently that technological advances, such as the ones outlined in this article, have led to the development of cutting-edge strategies that can be consciously paired with novel indications.”
BackgroundGonciarz, W., Chyb, M., & Chmiela, M. (2023) · Scientific Reports · doi:10.1038/s41598-023-30250-6 · Cited by 7 · cited 4×
“MACC1 then binds to synaptophysin to preserve the neuroendocrine phenotype, which is associated with increased invasiveness and the metastatic potential of GC.”
BackgroundInfluentialUrothelial cancer organoids: a tool for bladder cancer research
Meijer, R. P. (2021) · Der Pathologe · doi:10.1007/s00292-021-00988-9 · Cited by 6 · cited 1×
“33 Organoids are in vitro tissues that originate from human stem cells, organ-speci fi c progenitor cells, or even disassociated tumor tissues and are cultured in specialized ECM-based medium with relatively high success rates.”
BackgroundAsari, K., Sun, W. T., Kok, Z. H., Lam, Y. H., Ng, B. L., Saunders, V. A., White, D. L., Chuah, C. T. H., & Xiang, W. (2021) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000001028 · Cited by 6
Delays in cancer diagnosis: challenges and opportunities in Europe.
Renzi, C., Odelli, S., Morani, F., et al. (2023) · Acta bio-medica dell'Ateneo parmense/Acta biomedica · doi:10.23750/abm.v94is3.14513 · Cited by 5
Bathgate, J. R., Radler, D. R., Kurzer, M. S., & Samavat, H. (2023) · Nutrition Research · doi:10.1016/j.nutres.2023.03.001 · Cited by 5
Wilcox, C. M., Seay, T., Arcury, J. T., et al. (2010) · Scandinavian Journal of Gastroenterology · doi:10.3109/00365521.2010.536255 · Cited by 4
Zhang, C., Zhou, J., Hu, J., Lei, S., Yuan, M., Chen, L., Wang, G., & Qiu, Z. (2019) · RSC Advances · doi:10.1039/c9ra00429g · Cited by 3 · cited 1×
“184 A compelling study by Guo et al. demonstrated that administration of celecoxib post-diagnosis led to better overall survival rates in cancer patients, particularly those exhibiting positive PTGS2 expression combined with a phospha-tidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha…”
BackgroundSteeghs, N., Pruis, M. A., van Herpen, C., et al. (2022) · Investigational New Drugs · doi:10.1007/s10637-022-01318-3 · Cited by 2
(2022) · PubMed · Cited by 2
Sridhar, S. S., Ding, K., & Parulekar, W. R. (2021) · JAMA Oncology · doi:10.1001/jamaoncol.2020.8017 · Cited by 1
Cited by
Glaviano, A., Lau, H., Carter, L. M., Lee, E. H. C., Lam, H. Y., Okina, E., Tan, D. J. J., Tan, W., Ang, H. L., Carbone, D., et al. (2025) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01634-6 · Cited by 183
Applications of Artificial Intelligence in Drug Repurposing
Wan, Z., Sun, X., Li, Y., Chu, T., Hao, X., Cao, Y., & Zhang, P. (2025) · Advanced Science · doi:10.1002/advs.202411325 · Cited by 126
A review of the current trends in computational approaches in drug design and metabolism
Ouma, R. B. O., Ngari, S. M., & Kibet, J. K. (2024) · Discover Public Health · doi:10.1186/s12982-024-00229-3 · Cited by 95
“Similarly, bufulfone and chlorambucil which were initially developed as alkylating agents based on toxic chemical warfare agent mustard gas, have been repurposed for treating leukemia [55].”
Artificial Intelligence in Head and Neck Cancer: Innovations, Applications, and Future Directions
Pham, T. D., Teh, M., Chatzopoulou, D., Holmes, S., & Coulthard, P. (2024) · Current Oncology · doi:10.3390/curroncol31090389 · Cited by 88
“For instance, drugs initially developed for other cancers or diseases may exhibit potential efficacy against HNC, offering a faster and more cost-effective route to developing new treatments [156,157].”
BackgroundAn Open Access Database of Licensed Cancer Drugs
Pantziarka, P., Capistrano, R., Potter, A. D., Vandeborne, L., & Bouche, G. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.627574 · Cited by 70
Metadata
- Authors
- Xia, Y., Sun, M., Huang, H., & Jin, W.-L.
- Affiliations
- Johns Hopkins University (US)
- Guiyang Medical University (CN)
- Corresponding author
- Huang, Hai
- Venue
- Signal Transduction and Targeted Therapy
- Published
- 2024-04-19
- Volume
- 9
- Issue
- 1
- Pages
- 92-92
- ISSN
- 2059-3635 (ISSN-L)
- PMC
- PMC11026526
- OpenAlex
- W4394934376
- Cited by
- 443
- References
- 513
- Citations by year
- 2026: 168 · 2025: 214 · 2024: 60
- FWCI
- 12.35
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Signal Transduction and Targeted Therapy (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Natural Science Foundation of China (82060442)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Mechanisms and Therapy
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Keywords
- drug repurposing, cancer therapy, cancer hallmarks, tumor microenvironment, drug resistance, combination therapy, nanotechnology, topical drug delivery, anticancer agents, clinical translation
- MeSH terms
- Combined Modality Therapy, Humans, Neoplasms, Drug Delivery Systems, Treatment Outcome, Drug Repositioning, Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.